Sardesai Niranjan 4
4 · INOVIO PHARMACEUTICALS, INC. · Filed Mar 13, 2018
Insider Transaction Report
Form 4
Sardesai Niranjan
Chief Operating Officer
Transactions
- Tax Payment
Common Stock
2018-03-09$4.51/sh−6,896$31,101→ 108,705 total - Tax Payment
Common Stock
2018-03-10$4.51/sh−5,653$25,495→ 123,486 total - Exercise/Conversion
Restricted Stock Unit
2018-03-10−20,434→ 40,866 total→ Common Stock (20,434 underlying) - Exercise/Conversion
Common Stock
2018-03-10+20,434→ 129,139 total - Exercise/Conversion
Restricted Stock Unit
2018-03-09−25,000→ 25,000 total→ Common Stock (25,000 underlying) - Exercise/Conversion
Common Stock
2018-03-09+25,000→ 115,601 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 75,000 restricted stock units is as follows: 25,000 shares vested on March 9, 2017; 25,000 shares vested on March 9, 2018; 25,000 shares will vest on March 9, 2019. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.
- [F3]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares will vest on March 10, 2019; 20,433 shares will vest on March 10, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.
- [F4]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein.